Author(s): Nishimae K, Tsunoda N, Yokoyama Y, Kokuryo T, Iwakoshi A,
Abstract Share this page
Abstract BACKGROUND: In patients with luminal-type breast cancer (positive for ER and/or PgR), a complete consensus on the threshold indication for a combination of chemotherapy and endocrine therapy has not been achieved, especially for patients with HER2-negative luminal type (HNLT). Girdin, an actin-binding Akt substrate, plays a crucial role in the migration of cancer cells. This study examined the expression of Girdin in relation to clinicopathological features and other immunohistochemical markers (HER2, Ki-67), especially in patients with HNLT breast cancer. METHODS: One hundred one breast cancer patients who underwent surgery were evaluated. Immunohistochemical staining was performed for Girdin and other biomarkers, such as ER, PgR, HER2, and Ki-67. RESULTS: Positive expression of Girdin was observed in 26 patients. The expression of Girdin was significantly associated with the incidence of lymph node metastases (p = 0.001). Among the other examined biomarkers, positive expression of Ki-67 also showed a significant association with the incidence of lymph node metastases (p = 0.04). In the HNLT breast cancer patients (n = 73), the 5-year recurrence-free survival rate was significantly lower (57 \%) in patients with positive expression of both Girdin and Ki-67 than the rate in other patients (92 \%) (p = 0.002). CONCLUSION: This study demonstrated that the expression of Girdin in invasive breast cancer is strongly associated with lymph node metastasis. The expression status of Girdin and Ki-67 can be a useful biomarker in stratifying patients with HNLT breast cancer into those with high risk of recurrence and the need for additional chemotherapy.
This article was published in Breast Cancer
and referenced in Journal of Carcinogenesis & Mutagenesis